Rehydra+ Wellness review
Named clinicians, cure claim
A Texas practice with a named medical team and a deep peptide catalog — whose NAD+ page claims the treatment "may help cure addiction."
Our verdict
Rehydra+ has real substance behind it: a named medical director, a nurse practitioner and a second physician listed by name, a LegitScript claim, a genuinely deep peptide catalog sold by supply block, and a company history in mobile IV therapy that explains how it got here. It is let down by its own copy. The NAD+ product page states that the treatment "may help cure addiction" — a cure claim attached to a compounded, non-FDA-approved drug, which is precisely the category of statement the FDA cites telehealth sellers for, and nothing on the page walks it back. Add an unnamed pharmacy, an unpublished list of the 20 states it serves, and a no-refunds-once-shipped policy, and the result is a provider worth considering on catalog depth while discounting everything its marketing copy asserts.
Disclosure: Aminoscope is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. This never affects our rankings or verdicts. How we make money.
At a glance
- Category
- GLP-1 telehealth
- Access
- Dose-tiered: semaglutide $119/$169/$229, tirzepatide $169/$289/$419 — the entry price is the lowest dose only; 20 states, not listed
- Medications
- Compounded semaglutide · Compounded tirzepatide
- Insurance
- Cash-pay, no insurance
- Visit
- Quiz intake / Async intake
- Availability
- 20 states, not listed
- LegitScript
- Certified
- Updated
- August 2026
Popular alternative
Enhance MD
Lab-guided treatment under ongoing physician oversight
Check Enhance MD availability →What it is
A Texas telehealth practice that grew out of a mobile IV-therapy business, now selling compounded GLP-1s, testosterone therapy, and one of the broader peptide catalogs on this board through a WooCommerce storefront.
How it works
You complete an online intake form and are connected with a licensed provider through a third-party provider network; the appointment is conducted remotely, and if approved, medication ships directly to you. Rehydra+ is one of the few providers here to name its clinical team: John H. Hamilton, MD as medical director, Angie Tuzson as nurse practitioner, and Jared Folwell, MD, alongside owner Ronelle Motycka and CFO Josh Motycka. It claims LegitScript certification. Fulfillment is described only as "compounding pharmacy partners" — no pharmacy is named anywhere. The practice states it serves 20 states but does not publish which 20. Its terms are governed by Texas law with disputes venued in Bexar County.
Pricing transparency
Sold by supply block rather than a flat monthly rate, which makes it harder to compare but is honest about what you receive. GLP-1s run on a dose-scaled subscription ladder: semaglutide $119, $169 or $229 a month across three dose tiers, tirzepatide $169, $289 or $419 on the same structure — so the $119 entry price applies at 0.25–0.5 mg and rises as a clinician titrates you up. One-time supply blocks are also sold, from $149 to $749 for semaglutide and $219 to $1,419 for tirzepatide depending on dose and whether you buy four, eight or twelve weeks; there are also 600-unit promotional blocks at $899 and $999. Peptides: BPC-157 $320–$499 and KPV $320–$499 (45 or 90 days, oral or injectable), a BPC-157/TB-500 combination $380–$559, sermorelin $250–$449, tesamorelin $399–$899, GHK-Cu $220–$329, MOTS-c $399, and two proprietary stacks, GLOW at $299 and KLOW at $399. NAD+ is $279–$619 by route and supply length. Testosterone therapy is a flat $399. All prescription sales are final — no refunds once an order ships.
Branded vs compounded
All compounded and not FDA-approved. The peptide catalog is unusually deep and includes several compounds — BPC-157, KPV and TB-500 among them — that the FDA's Pharmacy Compounding Advisory Committee voted in July 2026 to recommend for the 503A bulk-substances list; that vote was non-binding and does not change their current status, but it is the relevant regulatory backdrop. What we cannot overlook is the NAD+ page. Its product description states that "NAD+-replacement treatment may help cure addiction while promoting mitochondrial health and homeostasis, genomic stability, neuroprotection, healthy aging, and lifespan." No NAD+ product has evidence for curing anything; injected NAD+ has no controlled human outcome trials at all, and the randomized evidence belongs to the oral NR and NMN precursors, where a raised blood level is the demonstrated endpoint. A cure claim on a compounded drug is a compliance exposure for the seller and a straightforwardly misleading statement for the reader. Its Lipo-Plus page uses softer but similar language about eliminating fatty deposits.
Pros and watch-outs
What we like
- Names a full clinical team, including a medical director, by name and role
- Claims LegitScript certification
- One of the deeper peptide catalogs on this board — BPC-157, TB-500, KPV, MOTS-c, GHK-Cu, sermorelin, tesamorelin and two blends
- Sells testosterone therapy alongside GLP-1s and peptides, so one practice covers three lines
- Supply-block pricing is explicit about dose, route and duration rather than hiding them behind a monthly figure
- A real operating history — the business grew out of mobile IV therapy rather than launching as a storefront
Watch-outs
- Its NAD+ product page claims the treatment "may help cure addiction" — an unsupported cure claim on a compounded drug
- No compounding pharmacy is named anywhere on the site
- Serves 20 states but never publishes which 20
- All prescription sales are final; no refunds once an order ships
- The $119 GLP-1 entry price applies only at the lowest dose tier and roughly doubles as you titrate
- The testosterone product page states one price without specifying ester, route, dose or supply length, and describes no lab-gating requirement
Best for
Buyers who want a deep peptide catalog in defined 45-, 90-day or multi-week supply blocks from a practice that names its clinicians, and who will judge the products on the evidence rather than the product copy.
Who should look elsewhere
Anyone who needs to know which pharmacy fills their prescription, anyone who wants to confirm state coverage before starting, or anyone who would rather not buy from a seller making cure claims.
The evidence behind what Rehydra+ Wellness prescribes
We grade the molecules, not the marketing. Here is what the human data actually shows for each thing on their menu.
- What the semaglutide weight-loss trials actually showed
STEP 1, STEP 4, and SELECT — the efficacy, the rebound, and the cardiovascular signal, read straight from the primary literature.
- Tirzepatide vs semaglutide for weight loss: what the trials actually support
Most comparisons are cross-trial. Only SURPASS-2 and SURMOUNT-5 randomized one drug against the other — here's the precise distinction.
- BPC-157 dosage and safety: why there is no validated human dose
The honest answer to a heavily-searched query: no established human dose, no dose-ranging trial, no approval, and no long-term safety data. Here is why.
- TB-500 and thymosin beta-4: separating the trials from the hype
Real Phase 2 dry-eye data, deep preclinical neuro/cardiac work, and a recovery-market use that was never actually tested.
- KPV peptide: what the evidence actually shows (benefits, dosage talk, and side effects)
KPV is the anti-inflammatory tripeptide tail of α-MSH, sold for gut, inflammation, wound-healing and skin. The mechanism is real and the mouse data are real — but there are essentially no human trials. A straight read of where the science stands.
- MOTS-c: real mitochondrial biology, absent human evidence
A genuine mitochondrial-derived peptide with interesting rodent data on metabolism and exercise — but no human outcome trials. Promising biology, not a proven therapeutic.
- Sermorelin: a real GHRH drug, read against the anti-aging pitch
An approved growth-hormone-releasing analog with a pediatric track record — and a longevity case built more on biomarkers than outcomes.
- Tesamorelin (Egrifta): what it's actually FDA-approved for, and the evidence
A real, approved GHRH analog — for HIV-associated lipodystrophy specifically. What the pivotal trials showed, and why the longevity use is an extrapolation.
- GHK-Cu: the copper peptide between real skincare and overclaim
A decades-deep molecule with a credible topical story — and systemic anti-aging claims that outrun the human data.
- NAD+ precursors (NR and NMN): what the human trials actually show
They raise NAD+ and look safe short-term — but human evidence is surrogate-marker level, and no trial shows they extend healthspan.
- TRT: what testosterone therapy is actually proven to do
An FDA-approved therapy for diagnosed hypogonadism — with real but moderate benefits (sexual function, mood; not vitality), cardiovascular non-inferiority in TRAVERSE, and a real fertility trade-off.
How Rehydra+ Wellness compares
A few alternatives worth a look, depending on what you’re optimizing for.
PeptiBuyers who want the widest set of GLP-1 routes with a price published against each
See Pepti →
the edit.Buyers who want the practice, pharmacy and management company all named before they pay
See the edit. →
AurenRxBuyers who want a named pharmacy and will read past the advertised headline price
See AurenRx →
Access & cost · Reviewed and last verified August 2026
How we assessed this. This review reflects Aminoscope’s own read of Rehydra+ Wellness’s publicly-stated model — pricing transparency, clinical oversight, medication clarity, and access — against our editorial methodology. We publish no fabricated ratings or first-hand outcomes. A partnership never changes the assessment — see how we make money.
Frequently asked
- Does NAD+ cure addiction, as Rehydra+'s page suggests?
- No. Rehydra+'s NAD+ product description states that the treatment "may help cure addiction," and there is no evidence for that. Injected NAD+ has no controlled human outcome trials of any kind. The randomized evidence in this area belongs to the oral precursors NR and NMN, and what those trials demonstrated was a raised blood NAD+ level, not a clinical outcome — let alone a cure for a chronic relapsing condition.
- Which states does Rehydra+ serve?
- Its About page says 20 states, but it does not publish the list anywhere on the site. You will need to confirm your own state before ordering.
- Is the $119 semaglutide price what I will pay long term?
- Probably not. Rehydra+ prices GLP-1s on a three-tier dose ladder, and $119 is the lowest tier, covering 0.25 and 0.5 mg weekly. As a clinician titrates you up, the price moves to $169 and then $229. Tirzepatide follows the same pattern at $169, $289 and $419.
- Can I get a refund if the medication does not suit me?
- No. Rehydra+ states that because of the nature of prescription and compounded medications it cannot accept returns or issue refunds once an order has shipped, and that all sales on prescription products are final.
- Which pharmacy fills a Rehydra+ prescription?
- The site does not say. It refers only to "compounding pharmacy partners" and an "affiliated pharmacy partner" without naming any of them — a gap worth weighing against providers on this board that name theirs.